Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Kymera Therapeutics

Tracked across 3 events · 18 articles · First seen Apr 13, 2026 · Last active Aug 10, 2026

Sentiment
32
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Regulatory
Impact: Kymera Therapeutics received Fast Track designation from the United States — Food and Drug Administration for its drug KT-621, which is expected to accelerate its development and potential approval for treating asthma.
Apr 13, 2026 · 6 articles
2 20
Business
Impact: Kymera Therapeutics appointed Penny Carlson as Senior Vice President, Development Operations, which is expected to strengthen its global clinical development operations. The company also announced the retirement of Jeremy Chadwick, its Chief Operating Officer, who will remain as an advisor.
Jun 08, 2026 · 6 articles
1 0
Business
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company developing oral therapies for neurologic diseases, announced the appointment of Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. Ridloff brings over two decades…
Impact: Kymera Therapeutics is mentioned as a company where Ridloff serves on the board.
Aug 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kymera Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.